Testing an immune medication for schizophrenia
Part of Mental health clinical trials.
This trial is testing a new medication that may reduce inflammation in the brain for people with schizophrenia. It focuses on those who have a specific immune marker, which might mean the medication could help with symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 64 years old.
- You must have a diagnosis of schizophrenia or schizoaffective disorder.
- You must have been on the same antipsychotic medication for at least 30 days, with no dose changes for at least 15 days.
- You must have had a blood test in the past showing high levels of AGA IgG antibodies (linked to gluten sensitivity).
- You cannot currently have an active infection, take immunosuppressive drugs, or use daily anti-inflammatory medications (like ibuprofen or high-dose aspirin).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 4 study tests how an anti-inflammatory approach affects people with schizophrenia or schizoaffective disorder who also have signs of body inflammation. It may help by targeting inflammation that could be linked to symptoms for some people.
This study looks at how immune system health relates to brain changes in people with schizophrenia. It uses brain imaging and electrical activity tests to understand these connections.
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This study looks at “biomarkers,” or blood measures, in people with schizophrenia who respond to clozapine. It may help researchers understand who benefits from clozapine and why, by linking test results to symptom changes.
This study looks at brain chemicals involved in “glutamate” and “GABA” signaling in people with schizophrenia (and separately in healthy volunteers). It may help researchers understand what’s going wrong in the brain and guide future treatments.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.